10-Q: Kaya Holdings Reports Q1 2024 Results, Focuses on Psychedelic Treatment Center Launch

Kaya Holdings reported a net loss for Q1 2024, driven by changes in derivative liabilities, while preparing to launch its flagship psilocybin treatment center.

Summary

• Kaya Holdings, Inc. reported a net loss of $1,105,680 for the first quarter of 2024, compared to a net income of $34,933 for the same period in 2023.
• The company's revenue decreased to $28,009 in Q1 2024 from $48,245 in Q1 2023, primarily due to a reduced retail footprint in Oregon.
• The net loss was largely attributed to changes in derivative liabilities, which resulted in a loss of $621,921 in Q1 2024 compared to a gain of $542,983 in Q1 2023.
• Operating expenses decreased to $313,189 in Q1 2024 from $367,526 in Q1 2023, reflecting cost-saving measures.
• As of March 31, 2024, the company had a working capital deficiency of $8,154,313 and is dependent on its ability to raise capital.
• Kaya Holdings is preparing to launch its psilocybin treatment center, The Sacred Mushroom, with a targeted opening date of June 1, 2024, or sooner.
• The company received approximately $210,000 in additional capital from CVC in Q1 2024 and another $130,000 on May 1, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making progress in the psilocybin market and has secured additional funding, the significant net loss, declining revenue, and working capital deficiency raise concerns about its financial health. The lack of effective internal controls also contributes to a negative sentiment.

Positives

• The company is on track to launch its psilocybin treatment center, The Sacred Mushroom, in June 2024.
• Kaya Holdings secured additional funding of $210,000 in Q1 2024 and $130,000 on May 1, 2024, from CVC.
• Operating expenses decreased, indicating cost-saving measures.
• The company has an approved license for its psilocybin service center.

Negatives

• The company reported a significant net loss of $1,105,680 for Q1 2024.
• Revenue decreased to $28,009 in Q1 2024, down from $48,245 in Q1 2023.
• The company has a substantial working capital deficiency of $8,154,313.
• The company's financial results were negatively impacted by changes in derivative liabilities.
• The company closed its Portland, Oregon cannabis dispensary.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital.
• The company faces risks associated with the commercialization and success of its products and services.
• The company is subject to competition in both the cannabis and psychedelic medicine sectors.
• The company is subject to evolving interpretations of laws and regulations governing its operations.
• The company's internal controls over financial reporting are not effective.

Future Outlook

The company plans to use proceeds from financing transactions to fund its growth plan, including the development of its Oregon psilocybin business and international projects in Greece. Management believes that further proceeds combined with existing and anticipated revenues will alleviate the company's financial difficulties to a significant extent and will allow the company to meet its anticipated working capital needs for a period of between twelve and eighteen months from the date of this report.

Management Comments

• Management believes that further proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Companys financial difficulties to a significant extent.
• Management plans include the sale of additional equity and debt securities, alliances and/or partnerships, business transactions, and development of a unified brand.

Industry Context

The company is positioning itself to capitalize on the growing psychedelic therapeutics market, particularly in Oregon, which has legalized psilocybin for medical use. The company is also leveraging its experience in the cannabis industry to expand into international markets. The global psychedelic therapeutics market is estimated to reach US$ 8.31 billion by 2028, with a CAGR of 13.2% during the forecast period of 2022-2028.

Comparison to Industry Standards

• The company's financial performance is weak compared to industry standards, with a significant net loss and a substantial working capital deficiency.
• The company's revenue is significantly lower than that of established cannabis companies, reflecting its reduced retail footprint.
• The company's focus on psilocybin treatment centers is a strategic move to capitalize on a growing market, but it faces competition from other companies in the space, such as Compass Pathways, ATAI Life Sciences, and Cybin.
• The company's plan to offer a superior treatment experience at a lower price than competitors is a key differentiator, but it remains to be seen if this will be successful.
• The company's international expansion plans in Greece are in line with industry trends, but they are subject to regulatory and financial risks.

Legal Proceedings

• The company is involved in a lawsuit with P3 Distributing LLC for unpaid vendor invoices.
• The company is involved in a legal dispute with Law Offices of Ross Day, which is currently in mediation.

Related Party Transactions

• The company has a $250,000 non-convertible note payable to a related party.
• The company has accrued compensation due to Tudog International Consulting, Inc. and BMN Consultants, Inc., which are related parties.
• The company has a loan payable to a stockholder.

Stakeholder Impact

• Shareholders are impacted by the company's net loss and working capital deficiency.
• Employees are impacted by the company's cost-saving measures and potential future hiring.
• Customers are impacted by the company's closure of its Portland cannabis dispensary and the upcoming launch of its psilocybin treatment center.
• Creditors are impacted by the company's debt obligations and its ability to repay them.
• Suppliers are impacted by the company's financial difficulties and its ability to pay for goods and services.

Next Steps

• The company plans to launch The Sacred Mushroom psilocybin treatment center in June 2024.
• The company will continue to seek additional financing to fund its operations.
• The company will continue to develop its international projects in Greece.
• The company will evaluate redeploying its remaining cannabis dispensary license to serve as a delivery hub.

Key Dates

Keywords

psilocybin, psychedelic treatment, cannabis, Kaya Holdings, financial results, derivative liabilities, working capital, The Sacred Mushroom, Oregon, CVC